X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (104) 104
glaucoma (91) 91
ophthalmology (86) 86
male (66) 66
index medicus (61) 61
female (60) 60
aged (52) 52
middle aged (52) 52
intraocular pressure - drug effects (50) 50
ocular hypertension - chemically induced (36) 36
aged, 80 and over (35) 35
intraocular pressure (32) 32
adult (28) 28
macular degeneration (28) 28
retrospective studies (26) 26
risk factors (25) 25
glucocorticoids - adverse effects (24) 24
eye (23) 23
eye diseases (22) 22
injections (22) 22
vascular endothelial growth factor a - antagonists & inhibitors (21) 21
intravitreal injections (20) 20
triamcinolone acetonide - adverse effects (20) 20
vitreous body (20) 20
surgery (19) 19
bevacizumab (18) 18
animals (17) 17
prospective studies (17) 17
ranibizumab (17) 17
angiogenesis inhibitors - adverse effects (16) 16
diagnosis (16) 16
intraocular-pressure (16) 16
tonometry, ocular (16) 16
diabetic retinopathy (15) 15
medicine & public health (15) 15
open-angle glaucoma (15) 15
therapy (15) 15
diabetic macular edema (14) 14
follow-up studies (14) 14
triamcinolone (14) 14
genetic structures (13) 13
ocular hypertension (13) 13
age (12) 12
angiogenesis inhibitors - administration & dosage (12) 12
glaucoma - drug therapy (12) 12
hypertension (12) 12
injection (12) 12
pharmacology & pharmacy (12) 12
trabeculectomy (12) 12
drug therapy (11) 11
glaucoma - surgery (11) 11
glucocorticoids - administration & dosage (11) 11
macular degeneration - drug therapy (11) 11
antibodies, monoclonal, humanized - adverse effects (10) 10
complications (10) 10
diabetes (10) 10
fluorescein angiography (10) 10
glaucoma - chemically induced (10) 10
ocular hypertension - drug therapy (10) 10
retinal vein occlusion (10) 10
sense organs (10) 10
treatment outcome (10) 10
visual acuity (10) 10
age-related macular degeneration (9) 9
antihypertensive agents - therapeutic use (9) 9
degeneration (9) 9
health aspects (9) 9
internal medicine (9) 9
ocular hypertension - physiopathology (9) 9
research (9) 9
safety (9) 9
vascular endothelial growth factor (9) 9
cataracts (8) 8
choroidal neovascularization - drug therapy (8) 8
corticosteroids (8) 8
glaucoma, open-angle - drug therapy (8) 8
prevalence (8) 8
time factors (8) 8
triamcinolone acetonide - administration & dosage (8) 8
vitrectomy (8) 8
antibodies, monoclonal, humanized - administration & dosage (7) 7
cornea (7) 7
inflammation (7) 7
macular edema - drug therapy (7) 7
physiological aspects (7) 7
postoperative complications (7) 7
adolescent (6) 6
antibodies, monoclonal - adverse effects (6) 6
antibodies, monoclonal, humanized (6) 6
antihypertensive agents - adverse effects (6) 6
choroidal neovascularization (6) 6
disease models, animal (6) 6
edema (6) 6
eye diseases - drug therapy (6) 6
glaucoma - ophthalmology (6) 6
incidence (6) 6
intravitreal triamcinolone (6) 6
pharmacology/toxicology (6) 6
retina (6) 6
retinal diseases - drug therapy (6) 6
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Ophthalmology, ISSN 0161-6420, 07/2015, Volume 122, Issue 7, pp. 1438 - 1451
Journal Article
Retina, ISSN 0275-004X, 10/2015, Volume 35, Issue 10, pp. 1992 - 2000
Journal Article
Retina, ISSN 0275-004X, 09/2008, Volume 28, Issue 8, pp. 1151 - 1158
Purpose: To systematically study potential adverse events associated with the use of intraocular bevacizumab at a single medical center. Methods: Retrospective... 
Macular degeneration | Neovascular glaucoma | Retinal pigment epithelial detachment | Adverse events | Choroidal neovascularization | Diabetic macular edema | Retinal vascular occlusion | Retinal pigment epithelial tear | Avastin | Bevacizumab | UNITED-STATES | retinal pigment epithelial tear | choroidal neovascularization | SAFETY | PATHOLOGICAL MYOPIA | adverse events | macular degeneration | retinal vascular occlusion | IMPAIRMENT | TEARS | INJECTION | neovascular glaucoma | PIGMENT EPITHELIUM | bevacizumab | OPHTHALMOLOGY | retinal pigment epithelial detachment | AGERELATED MACULAR DEGENERATION | RANIBIZUMAB | diabetic macular edema | Retinal Perforations - chemically induced | Follow-Up Studies | Humans | Antibodies, Monoclonal - adverse effects | Male | Macular Degeneration - drug therapy | Retinal Detachment - complications | Eye Diseases - chemically induced | Antibodies, Monoclonal, Humanized | Angiogenesis Inhibitors - administration & dosage | Choroidal Neovascularization - drug therapy | Choroid Diseases - drug therapy | Hypertension - chemically induced | Aged, 80 and over | Vitreous Body | Adult | Female | Retrospective Studies | Angiogenesis Inhibitors - adverse effects | Headache - chemically induced | Retinal Pigment Epithelium - drug effects | Macular Degeneration - complications | Retinal Vessels - drug effects | Injections | Antibodies, Monoclonal - administration & dosage | Aged | Retinal Diseases - drug therapy | Choroidal Neovascularization - complications | Index Medicus
Journal Article
American Journal of Ophthalmology, ISSN 0002-9394, 2005, Volume 139, Issue 3, pp. 421 - 428
Journal Article
1982, ISBN 9780801641954, xii, 429
Book
Journal Article
American Journal of Ophthalmology, ISSN 0002-9394, 2014, Volume 158, Issue 2, pp. 319 - 327.e2
Purpose To determine the intravitreal anti–vascular endothelial growth factor (VEGF) injection techniques and preferences within the retinal community and to... 
Ophthalmology | REPACKAGED BEVACIZUMAB | FACTOR AGENTS | NEEDLES | PEGAPTANIB | OPHTHALMOLOGY | MACULAR DEGENERATION | INJECTIONS | TRIAMCINOLONE | IOP | HYPERTENSION | RANIBIZUMAB | United States - epidemiology | Intraocular Pressure - drug effects | Prevalence | Prognosis | Prospective Studies | Ocular Hypertension - physiopathology | Recombinant Fusion Proteins - adverse effects | Humans | Intravitreal Injections - methods | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Macular Degeneration - drug therapy | Bevacizumab | Angiogenesis Inhibitors - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Ranibizumab | Ocular Hypertension - chemically induced | Surveys and Questionnaires | Angiogenesis Inhibitors - adverse effects | Ocular Hypertension - epidemiology | Recombinant Fusion Proteins - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Clinical Competence | Cross-Sectional Studies | Risk Factors | Receptors, Vascular Endothelial Growth Factor - administration & dosage | Receptors, Vascular Endothelial Growth Factor - adverse effects | Macular degeneration | Medical colleges | Vascular endothelial growth factor | Consulting services | Glaucoma | Confidence intervals | Statistical analysis | Retina | Cotton | Multivariate analysis | Eyes & eyesight
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.